Evidence map›Paper›PMID 41762177›Full record

ArticleJACC. Advances2026

Second-Generation Aldosterone Synthase Inhibitors for Hypertension: A Bayesian Meta-Analysis of Randomized Trials.

Flavia Queiroga, Beatriz Araújo, André Rivera, Leo Consoli, Aditi Ujjawal, Ensieh Sadat Mansouri, Maria Antonia Costa Cruz Akabane, Nelson I Barrera, Ana Beatriz Valverde Ramos, Asad Iqbal and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Flavia QueirogaDivision of General Internal Medicine, Department of Medicine, Emory University, Atlanta, Georgia, USA.
Beatriz AraújoDepartment of Medicine, Universidade Nove de Julho, São Bernardo do Campo, Brazil.
André RiveraDepartment of Medicine, Universidade Nove de Julho, São Bernardo do Campo, Brazil.
Leo ConsoliDepartment of Medicine, Universidade Federal da Bahia, Bahia, Brazil.
Aditi UjjawalDivision of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Ensieh Sadat MansouriDepartment of Medicine, University of Medical Sciences, Tehran, Iran.
Maria Antonia Costa Cruz AkabaneDepartment of Medicine, Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil.
Nelson I BarreraDivision of Cardiology, Columbia University Medical Center, New York, New York, USA.
Ana Beatriz Valverde RamosDepartment of Medicine, Pontificia Universidade Catolica do Parana, Parana, Brazil.
Asad IqbalDepartment of Medicine, Bacha Khan Medical College, Mardan, Pakistan.
Marcelo BragaDepartment of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Anna K KrawiszDivision of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Paula DiboDivision of General Internal Medicine, Department of Medicine, Emory University, Atlanta, Georgia, USA.
Deepak L BhattMount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: DLBhattMD@post.Harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSecond-generation aldosterone-synthase inhibitors (ASIs) may offer a novel treatment for hypertension.

objectivesThe objective of the study was to assess the efficacy and safety of ASIs in this clinical setting.

methodsWe searched major databases for randomized controlled trials (RCTs) assessing ASIs (baxdrostat, lorundrostat, and vicadrostat) in patients with hypertension. For efficacy outcomes, mean differences (MD) with 95% credible intervals (CrIs) were estimated using a Bayesian random-effects model. For adverse events, OR with 95% CrI were estimated using a Bayesian binomial-normal hierarchical model. The protocol was registered in Prospective Register of Systematic Reviews (CRD420251132306).

resultsEight RCTs were included (n = 3,369; 2,430 [72%] randomized to ASI). ASI reduced systolic blood pressure (SBP) (MD: -6.7 mm Hg; CrI: -8.78, -4.59; τ

conclusionsSecond-generation ASIs had a high likelihood of a clinically significant reduction in SBP compared with placebo. However, hyperkalemia, hyponatremia, and hypotension were more frequent with ASIs.

Indexed as

aldosteronealdosterone synthase inhibitorschronic kidney diseasehypertension

Identifiers

PMID41762177
PMCPMC13100762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.